Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 729-742

  Das, Surajit ^a   Ng, Ka Yun ^a,b   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bead; Delayed release; Formulation parameters; Resveratrol; Zn pectinate

Indexed keywords

CALCIUM PECTINATE; NANOBEAD; RESVERATROL; UNCLASSIFIED DRUG; ZINC PECTINATE; DELAYED RELEASE FORMULATION; MICROCAPSULE; PECTIN; STILBENE DERIVATIVE; VASODILATOR AGENT;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG RETENTION; ENCAPSULATION; ENZYME DEGRADATION; ENZYME STABILITY; MOISTURE; MORPHOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; ABSORPTION; CHEMISTRY; DIFFUSION; DRUG FORMULATION; MICROCAPSULE; PROCEDURES; SYNTHESIS;

ABSORPTION; CAPSULES; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG COMPOUNDING; PECTINS; STILBENES; VASODILATOR AGENTS;

EID: 77954818667     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9435-7     Document Type: Article

References (36)

1. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218-20.
3. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets. 2006;7(4):423-42.
4. Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. 2008;25(11):2593-600.
5. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A et al. Resveratrol improves health and survival of mice on a highcalorie diet. Nature. 2006;444(7117):337-42.
6. Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol. 2004;67(7):1399-410.
7. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol. 2006;147(8):873-85.
8. Tessitore L, Davit A, Sarotto I, Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis. 2000;21(8):1619-22.
9. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates hostdefense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer. 2001;39(1):102-7.
10. Basit AW. Advances in colonic drug delivery. Drugs. 2005;65(14):1991- 2007.
11. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev. 2005;57(2):247-65.
12. Liu L, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials. 2003;24(19):3333-43.
13. Wakerly Z, Fell J, Attwood D, Parkins D. Studies on amidated pectins as potential carriers in colonic drug delivery. J Pharm Pharmacol. 1997;49(6):622-5. (Pubitemid 27281432)
14. Thakur BR, Singh RK, Handa AK. Chemistry and uses of pectina review. Crit Rev Food Sci Nutr. 1997;37(1):47-73.
15. Maestrelli F, Cirri M, Corti G, Mennini N, Mura P. Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery. Eur J Pharm Biopharm. 2008;69(2):508-18.
16. Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J Control Release. 1998;55(1):67-77.
17. Sriamornsak P. Effect of calcium concentration, hardening agent and drying condition on release characteristics of oral proteins from calcium pectinate gel beads. Eur J Pharm Sci. 1999;8(3):221-7.
18. Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P. Microspheres for colonic delivery of ketoprofen-hydroxypropyl-betacyclodextrin complex. Eur J Pharm Sci. 2008;34(1):1-11.
19. Dupuis G, Chambin O, Génelot C, Champion D, Pourcelot Y. Colonic drug delivery: influence of cross-linking agent on pectin beads properties and role of the shell capsule type. Drug Dev Ind Pharm. 2006;32(7):847-55.
20. El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm. 2002;232(1-2):199-211.
21. Chambin O, Dupuis G, Champion D, Voilley A, Pourcelot Y. Colon-specific drug delivery: influence of solution reticulation properties upon pectin beads performance. Int J Pharm. 2006;321(1-2):86-93.
22. Das S, Ng K.-Y. Resveratrol-loaded calcium-pectinate beads: effects of formulation parameters on drug release and bead characteristics. J Pharm Sci. 2010;99(2):840-60.
23. Atyabi F, Majzoob S, Iman M, Salehi M, Dorkoosh F. In vitro evaluation and modification of pectinate gel beads containing trimethyl chitosan, as a multi-particulate system for delivery of water-soluble macromolecules to colon. Carbohydr Polym. 2005;61(1):39-51.
24. Wong TW, Nurjaya S. Drug release property of chitosanpectinate beads and its changes under the influence of microwave. Eur J Pharm Biopharm. 2008;69(1):176-88.
25. Bourgeois S, Tsapis N, Honnas H, Andremont A, Shakweh M, Besnard M et al. Colonic delivery of beta-lactamases does not affect amoxicillin pharmacokinetics in rats. J Pharm Sci. 2008;97(5):1853-63.
26. Grant GT, Morris ER, Rees DA. Biological interactions between polysaccharides and divalent cations: the egg box model. FEBS Lett. 1973;32(1):195-8.
27. Bourgeois S, Gernet M, Pradeau D, Andremont A, Fattal E. Evaluation of critical formulation parameters influencing the bioactivity of beta-lactamases entrapped in pectin beads. Int J Pharm. 2006;324(1):2-9.
28. Drinker KR, Thompson PK, Marsh M. An investigation of the effect upon rats of long continued ingestion of zinc compounds, with a special reference to the relation of zinc excretion to zinc intake. Am J Physiol. 1927;80:284-306.
29. Wellner N, Kacurakova M, Malovikova A, Wilson RH, Belton PS. FT-IR study of pectate and pectinate gels formed by divalent cations. Carbohydr Res. 1998;308(1-2):123-31.
30. Dronnet VM, Renard C M G C, Axelos M A V, Thibault JF. Characterisation and selectivity of divalent metal ions binding by citrus and sugar-beet pectins. Carbohydr Polym. 1996;30(4):253-63.
31. Pillay V, Fassihi R. In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract. I. Comparison of pH-responsive drug release and associated kinetics. J Control Release. 1999;59(2):229-42.
32. Cardoso SM, Coimbra MA, Lopes da Silva JA. JA. Temperature dependence of the formation and melting of pectin-Ca 2+ networks: A rheological study. Food Hydrocoll. 2003;17(6):801-7.
33. Gilsenan PM, Richardson RK, Morris ER. Thermally reversible acid-induced gelation of low-methoxy pectin. Carbohydr Polym. 2000;41(4):339-49.
34. Lootens D, Capel F, Durand D, Nicolai T, Boulenguer P, Langendorff V. Influence of pH, Ca concentration, temperature and amidation on the gelation of low methoxyl pectin. Food Hydrocoll. 2003;17(3):237-44.
35. Sriamornsak P, Nunthanid J. Calcium pectinate gel beads for controlled release drug delivery: I. Preparation and in vitro release studies. Int J Pharm. 1998;160(2):207-12.
36. Sriamornsak P. Investigation of pectin as a carrier for oral delivery of proteins using calcium pectinate gel beads. Int J Pharm. 1998;169(2):213-20.